Article detail · 2023 · article
Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
Data source split
- YÖKSİSYÖKSİS article record
- YÖKSİS venueGalenos Yayinevi
- Catalog match (ISSN)European Journal of Breast Health
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
- Semantic Scholarcitation count (not merged with OpenAlex)
Abstract
Objective: The role of baseline and post-treatment standardized uptake value (SUV max ) values in predicting pathological response in patients with breast cancer after neoadjuvant chemotherapy (NAC). Materials and Methods:Thirty patients with invasive ductal breast cancer were included in this retrospective study.F-18 fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) examinations were performed before and after NAC.Pretreatment SUV max (SUV max I), post-treatment SUV max (SUV max II) and ΔSUV max values of primary breast cancer were obtained.Breast tumor pathology preparations were examined for the evaluation of tumor response according to the Miller and Payne classification.Patients were grouped as responding to treatment (pCR) and unresponsive to treatment (nonpCR).In all analyses, p<0.05 was considered statistically significant.Results: The mean age of the 30 patients included in the study was 51.2±11.98 years.In the study-defined grouping, 13 patients (43.3%) were nonresponders and 17 patients (56.7%) were responders.ΔSUV max was significantly greater in the responders group compared to the nonresponders group, while SUV max II was lower (p = 0.001 and p = 0.004, respectively).There was no significant difference between the responders and nonresponders in terms of age, tumor diameter, and SUV max I values.Multivariate logistic regression analysis showed ΔSUV max to be the only independent predictive factor for pCR.Conclusion: F-18 FDG PET/CT was an effective method in evaluating the treatment response after NAC in breast cancer, and ΔSUV max and posttreatment SUV max can be used to predict the response of the primary tumor to treatment.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
9citationsOpenAlex · cited_by_count (cache / database)
9 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- 2025 Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1–2 Breast Cancer: An Internally Validated PET/CT-Integrated NomogramCitations 1 · OpenAlex
- 2025 Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1–2 Breast Cancer: An Internally Validated PET/CT-Integrated NomogramCitations 1 · OpenAlex
- 2025 Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1–2 Breast Cancer: An Internally Validated PET/CT-Integrated NomogramCitations 1 · OpenAlex
- 2025 Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1–2 Breast Cancer: An Internally Validated PET/CT-Integrated NomogramCitations 1 · OpenAlex
- 2025 Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1–2 Breast Cancer: An Internally Validated PET/CT-Integrated NomogramCitations 1 · OpenAlex
- 2024 Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer?Citations 1 · OpenAlex
- 2024 Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer?Citations 1 · OpenAlex
- 2025 Does FDG PETCT have a predictive value for neoadjuvant chemotherapy response in nonmetastatic breast cancer?Citations 0 · OpenAlex
- 2024 Does FDG PETCT have a predictive value for neoadjuvant chemotherapy response in nonmetastatic breast cancer?Citations 0 · OpenAlex